Alzheimer’s Therapeutics Market

2. Unaffiliated Platform Trial — jRCT2031250327

• jRCT ID: jRCT2031250327
• Phase: Phase III mult icenter randomized, double-blind, placebo-controlled platform study of trontinemab in early symptomatic AD (MCI to mild dementia) in Japan.
• Drug Candidate: Trontinemab
• MOA: Anti-amyloid/tau antibody (presumed; registry does not list full MOA)
• Company Sponsor: Listed under a clinical site/medical organization — not a Japanese pharmaceutical company. (Included here for visibility because it is a Phase III platform trial in Japan but not company sponsored.)

3. ADEL, Inc. 

• Company & Country: ADEL, Inc. (South Korea)
• Drug Candidate: ADEL-Y01
• Clinical Phase: Early-stage human trials (clinical stage presumed Phase I/II) as per news reports citing US early-stage human trials.
• Mechanism of Action (MOA): Monoclonal antibody targeting tau acetylation, a post-translational modification implicated in tau aggregation and neurodegeneration in Alzheimer’s disease.
• Latest Developments / Regulatory Updates:
• • In December 2025, ADEL signed a $1.04 billion development deal with Sanofi to co-develop and commercialize ADEL-Y01 globally, reflecting confidence in its differentiated MOA and early clinical data.
• Clinical Trial Registry IDs:
• • ADEL-sponsored clinical trial registrations could be present on clinicaltrials.gov or Korean registries but are not yet identifiable with unique IDs publicly linked to ADEL-Y01 as of the latest search.

Alzheimer’s Disease Treatment Market

Although Alzheimer’s disease remains incurable, early diagnosis and timely intervention play a crucial role in symptom management and quality-of-life improvement. Current therapies primarily focus on symptomatic relief by modulating neurotransmitter activity, including acetylcholine and glutamate pathways. For more than a decade, acetylcholinesterase inhibitors and memantine have served as standard options for symptomatic management.

Recent regulatory approvals have marked a shift toward disease-modifying approaches. In July 2023, the US FDA approved LEQEMBI (lecanemab) for early Alzheimer’s disease, followed by approvals in Japan and the UK. Subsequently, KISUNLA (donanemab) received FDA approval in July 2024, representing another major milestone in early-stage Alzheimer’s treatment.

Access in-depth insights on late-stage Alzheimer’s drug development and upcoming market launches now - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Alzheimer’s Disease Pipeline Therapies and Key Companies

The Alzheimer’s disease pipeline continues to expand, with global players advancing innovative modalities. Notable candidates include BioVie’s Bezisterim, AB Science’s Masitinib, Annovis Bio’s Buntanetap, TauRx Therapeutics’ HMTM, Cassava Sciences’ Simufilam, Eli Lilly’s Remternetug, and Novo Nordisk’s Semaglutide, among others.

These therapies employ diverse mechanisms, such as anti-inflammatory pathways, neuroimmune modulation, translational inhibition of toxic proteins, and metabolic regulation, reflecting a shift toward multifaceted treatment strategies. Several of these agents are in Phase III development, with potential launches anticipated within the forecast horizon.

Recent Developments in the Alzheimer’s Disease Market